Impact BioMedical shares surge 67.94% intraday after amending merger agreement with Dr. Ashleys Bio Labs, extending deadline to July 1, 2026, and issuing 169.56M shares for 94.20% stake.

Impact BioMedical surged 67.94% intraday trading, as the company amended its merger agreement with Dr. Ashley's Bio Labs, extending the deadline to July 1, 2026, and issuing 169,560,000 shares as equity consideration (94.20% of the combined entity). The company specializes in developing proprietary biomedical technology platforms, including Linebacker for oncology and Equivir for antiviral applications, with global commercialization rights granted to ProPhase Labs.